Navigation Links
Alba Therapeutics Announces Phase IIb Clinical Trial for Oral AT-1001 for the Treatment of Celiac Disease
Date:9/19/2007

BALTIMORE, Sept. 19 /PRNewswire/ -- Alba Therapeutics Corporation today announced that it has dosed its first patient in a six-week Phase IIb trial with oral AT-1001, an inhibitor of gastrointestinal barrier dysfunction, for the maintenance of remission in patients with Celiac Disease (CD). The multi-center, double-blind, placebo-controlled, dose ranging study will evaluate the efficacy, safety and tolerability of AT-1001 in CD subjects during a six-week gluten challenge, while also testing components of a Celiac Disease activity rating index, a new patient-reported outcomes instrument. "This is Alba's fifth human trial with AT-1001 and highlights our efforts to develop paradigms for the treatment of CD and for the assessment of activity in this neglected disease" stated Dr. Blake Paterson, CEO of Alba. "Since there is no effective treatment for CD and no validated means of measuring disease progression, the successful completion of this study will be a tremendous step forward for Celiac patients."

About Celiac Disease

Celiac Disease ("CD") is a T-cell mediated auto-immune disease that occurs in genetically susceptible individuals and is characterized by small intestinal inflammation, injury and intolerance to gluten. According to the National Institutes of Health, CD affects approximately 3 million Americans. The only current treatment for CD is complete elimination of gluten from the diet, which results in remission for some patients.

About AT-1001

AT-1001 is an inhibitor of barrier dysfunction that has been shown to block intestinal permeability and the genesis of some autoimmune diseases, either as a result of reduction of antigen presentation to the body's immune system, or through some unknown inhibitory, direct effect on gastrointestinal associated lymphoid tissue. AT-1001 is orally formulated, has been granted "Fast Track" designation by the U.S. Food and Drug Administration for the treatment of Celiac Disease, and is also bein
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)...July 24 /PRNewswire-USNewswire/ -- Headlines claim...he whole story. The small scale,preliminary study...n,Reproduction, is based on recollected intake of ...oods. "This study is confounded by many,issues, th...t deal of,caution," warned Dr. Tammy Hedlund, a re...
(Date:7/24/2008)...OLIS, France, July 24 /- Ni... top-line results from the 52-week,open label safe...letion of,the 301 phase 3 study for naproxcinod. T...and efficacy was maintained for the one-year durat...bal assessment scale. In,addition, the results sho...
(Date:7/23/2008)...July 23 /PRNewswire-USNewswire/ -- The following w...hairman Conyers, Ranking Member Smith, and Members...o testify today., Since I appeared before this Co...better acquainted with the talented and dedicated ...he work they do, and I have come to,appreciate tha...
(Date:7/23/2008)...y 23 /- Dendreon Corporatio... the Independent Data,Monitoring Committee (IDMC) ...overall survival relating to the Company,s Phase 3... Treatment, also known as D9902B) clinical trial,o...any,s investigational,active cellular immunotherap...
Breaking Medicine Technology:Soyfoods Do Not Impact Sperm Count 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 3NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 4Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 2Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Study finds circumcision safe in both HIV infected and HIV uninfected men 20907 1Study finds circumcision safe in both HIV infected and HIV uninfected men 20907 2Study finds circumcision safe in both HIV infected and HIV uninfected men 20907 3Chinese Officials Cancel Dog Cull in Earthquake Zone 20905 1Chinese Officials Cancel Dog Cull in Earthquake Zone 20905 2Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma 2298 1Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma 2298 2Oticon Tapes Out Innovative Hearing Aid DSP Using Synopsys IC Compiler 20903 1Oticon Tapes Out Innovative Hearing Aid DSP Using Synopsys IC Compiler 20903 2Oticon Tapes Out Innovative Hearing Aid DSP Using Synopsys IC Compiler 20903 3
... Profile and Excellent,Pharmacokinetic Properties ...RNewswire/ --,CeNeRx BioPharma, Inc., a clinical s...tive treatments for diseases of the central,nervou...Phase I,clinical trial of Tyrima(TM), its lead can.... In this study, Tyrima was safe and well,tolerate...
...7 /PRNewswire-FirstCall/ -- CV,Therapeutics, Inc. ...ogy (JACC) has published data from the Ranolazine ... long-term therapy with,Ranexa(R) (ranolazine exte...d in patients with chronic stable angina who compl...led in the ROLE,program. , These data also suggest...
Other Medicine Technology:CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 2CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 3JACC Publishes Long-Term Safety and Tolerability Data from,Ranolazine Open Label Experience (ROLE) Program 2JACC Publishes Long-Term Safety and Tolerability Data from,Ranolazine Open Label Experience (ROLE) Program 3JACC Publishes Long-Term Safety and Tolerability Data from,Ranolazine Open Label Experience (ROLE) Program 4
(Date:7/25/2008)...s of Marketing Exclusivity Begins -, CORONA, Cali...aceuticals, Inc. (NYSE: WPI ), a leading specialt... subsidiary has commenced commercial,shipment of i... in the 40mg,strength from its Davie, Florida manu..., Watson has 180 days of marketing exclusivity for...
(Date:7/25/2008)...ion Executive, Robert J. Reilly, Joins Aethon Team...,( http://www.aethon.com ), the leading developer ...tics, today announced that Robert J. Reilly has,jo... Financial Officer., Reilly, who was most recentl...orporation,s Specialty Pharmacy Division, brings m...
(Date:7/25/2008)...ewswire/ -- The Elekta Family of Companies will,sh...ions at the 2008,American Association of Physicist... how the joint forces of Elekta, IMPAC and CMS are...g and delivery solutions that,streamline the treat...ients, as well as enhance clinician efficiency., ...
(Date:7/25/2008)...y 25 /PRNewswire/ -- AutoGenomics, Inc. today,anno...n Form S-1 with the,Securities and Exchange Commis...ing of shares of its common stock. The number of s...are expected to be offered by,AutoGenomics, Inc., ... been,determined., J.P. Morgan Securities Inc. is...
Breaking Medicine News(10 mins):Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2
...netary Fund (IMF) said that there would be a signi...had not set aside a plan of action against the avi...watchdog. It said that a pandemic would trigger sh...s commodities, tourism and trade would recede and ...
...ntists from Princeton University says that running...of exercising. The reserachers led by Elizabeth Go...science that running alone does not seem to genera...after running or exercising in pairs or in groups....
...ection for a zone in Torun, in northern Poland on ...ad swan was found. Polish vets confirmed the prese...he swan was found near the German border but the v...he bird had the potent strain that could infect hu...
...mbia and Maryland may stand to lose heavily in fed...cal health departments to record identities of peo... two jurisdictions figure among many in the countr...s using codes and not names. The Centers for Disea...
Other Medicine News:
2-ply material consisting of polyethylene film inner layer and non-woven outer layers.
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and
The cardiac blanket is pre-positioned at the waist during prep, unrolled upon closure of the saphenous vein graft incision, and inflated post-bypass.
The full access underbody blanket is positioned on the procedure table before the patient arrives to the room.
Medicine Products: